Michael Jaharis Net Worth

Since 1972, he landed the position of CEO and President of Key Pharmaceuticals until its merger with Schering-Plough Corporation more than a decade later. In 1988, Jaharis decided to found Kos Pharmaceuticals, Inc, the company that introduced Niaspan, a cholesterol-fighting drug that was later sold to Abbott Labs for $4.2 billion. Furthermore, Michael Jaharis established himself as a great philanthropist who has made generous contributions to various organizations like Weill Cornell Medical College of Cornell University, the Art Institute of Chicago, the Metropolitan Museum of Art and the Metropolitan Opera, as well as the Tufts University School of Medicine and the Columbia University Medical Center.